A Phase 2, Open-label, Multicenter Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Subjects With Non-transfusion-dependent Thalassemia
Phase of Trial: Phase II
Latest Information Update: 20 Dec 2018
At a glance
- Drugs Mitapivat (Primary)
- Indications Thalassaemia
- Focus Proof of concept; Therapeutic Use
- Sponsors Agios Pharmaceuticals
- 12 Dec 2018 Status changed from not yet recruiting to recruiting.
- 01 Nov 2018 According to an Agios Pharmaceuticals media release, the company is planning to Initiate this study by end of year 2018.
- 28 Sep 2018 Status changed from planning to not yet recruiting.